Loading...

Kelly Elizabeth Mccann

Title(s)HS Assistant Clinical Professor, Medicine
SchoolMedicine
Address760 Westwood Plaza 32-144
Los Angeles CA 90024
Phone(310) 998-4747
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Innovations in targeted therapies for triple negative breast cancer. Curr Opin Obstet Gynecol. 2021 Feb 01; 33(1):34-47. McCann KE, Hurvitz SA. PMID: 33093337.
      View in: PubMed   Mentions:    Fields:    
    2. Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs. 2019 Jul; 79(11):1217-1230. McCann KE, Hurvitz SA, McAndrew N. PMID: 31254268.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    3. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. Future Oncol. 2019 May; 15(15):1707-1715. McCann KE. PMID: 30912451.
      View in: PubMed   Mentions:
    4. Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. Curr Opin Obstet Gynecol. 2019 02; 31(1):12-17. McCann KE. PMID: 30540581.
      View in: PubMed   Mentions:
    5. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context. 2018; 7:212540. McCann KE, Hurvitz SA. PMID: 30116283.
      View in: PubMed   Mentions:
    6. Harnessing the immune system in the battle against breast cancer. Drugs Context. 2018; 7:212520. Nakasone ES, Hurvitz SA, McCann KE. PMID: 29456568.
      View in: PubMed   Mentions:
    7. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer. Curr Opin Obstet Gynecol. 2018 Feb; 30(1):7-16. McCann KE. PMID: 29251678.
      View in: PubMed   Mentions:
    8. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 2009 Jan 30; 323(5914):644-8. Venteicher AS, Abreu EB, Meng Z, McCann KE, Terns RM, Veenstra TD, Terns MP, Artandi SE. PMID: 19179534.
      View in: PubMed   Mentions:
    9. Radiosensitization of yeast cells by inhibition of histone h4 acetylation. Radiat Res. 2008 Nov; 170(5):618-627. Song S, McCann KE, Brown JM. PMID: 18959465.
      View in: PubMed   Mentions:
    10. A role for Lsmlp in response to ultraviolet-radiation damage in Saccharomyces cerevisiae. Radiat Res. 2008 Oct; 170(4):411-21. Spicakova T, McCann K, Brown JM. PMID: 19024647.
      View in: PubMed   Mentions:
    11. Global analysis of gene function in yeast by quantitative phenotypic profiling. Mol Syst Biol. 2006; 2:2006.0001. Brown JA, Sherlock G, Myers CL, Burrows NM, Deng C, Wu HI, McCann KE, Troyanskaya OG, Brown JM. PMID: 16738548.
      View in: PubMed   Mentions:
    Kelly's Networks
    Concepts (63)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑